The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 180, 8004 -8010
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werneck, M. B. F.
Right arrow Articles by Glimcher, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werneck, M. B. F.
Right arrow Articles by Glimcher, L. H.

T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease1

Miriam B. F. Werneck*,{dagger}, Geanncarlo Lugo-Villarino2,{ddagger}, Eun Sook Hwang, Harvey Cantor3,*,{dagger} and Laurie H. Glimcher3,{ddagger},§

* Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA 02115; {dagger} Department of Pathology and {ddagger} Department of Medicine, Harvard Medical School and § Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115; and College of Pharmacy and Division of Life and Pharmaceutical Science and Center for Cell Signaling and Drug Discovery Research, Ewha Womans University, Seoul, Republic of Korea


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Antitumor responses depend on type 1 immunity, which is severely impaired in mice deficient for the T-box expressed in T cells (T-bet) transcription factor. Both T-bet-deficient (T-bet–/–) NK and CTL show defective function, which can be overcome by strong stimuli due to the expression of eomesodermin, another member of the T-box family. The effective response from T-bet–/– mice to viral infection and tumor initiation corroborates with these findings. However, T-bet–/– animals fail to control cancer metastasis and are, therefore, highly susceptible to tumor spread. The mechanism of T-bet-dependent resistance to metastatic disease is not known. In this study, we show that T-bet plays a role in inhibiting cancer metastasis by regulating the longevity and function of NK cells. Our data demonstrate that the absence of a proper innate immune response driven by NK cells in T-bet–/– mice precludes the initiation of a potent adaptive response to tumors. Adoptive transfer of wild-type activated NK cells protects T-bet–/– animals after melanoma challenge showing that reconstitution of the NK compartment in these mice is sufficient to mediate a significant reduction in tumor burden. Transfer of T-bet–/– A-NK cells fails to do so, due to their reduced in vivo survival, inefficient lysis of cancer cells, and poor IFN-{gamma} production. Taken together, these results show for the first time an irreplaceable role for T-bet in the NK-mediated cross-talk between innate and adaptive immune responses to metastatic disease.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Although most tumors are weak stimulators of immunity, antitumor immune-responses are physiologically relevant and can retard tumor growth in vivo (1, 2, 3, 4, 5, 6). Immunologic protection reflects the combined impact of cells and cytokines belonging to the innate and adaptive immune systems. This includes NK cells and CTLs, as well as effector cytokines characteristic of type 1 immunity (7, 8, 9, 10, 11). In the latter case, factors such as IFN-{gamma} can directly inhibit the growth of tumor cells as well as promote the production of other type 1 cytokines and differentiation of cytotoxic NK and T cells (11, 12, 13, 14, 15). This cytokine milieu determines the differentiation fate of activated T lymphocytes and their development into Th/T cytotoxic (Tc)4 1 or 2 cells (14, 16). Hence, factors that regulate type 1 immunity are likely to alter the quality of antitumor responses.

The T-bet transcription factor is essential for the expression of genes that guide type 1 immune differentiation in naive T cells and other cells of the immune system. Furthermore, expression of T-bet redirects T cell differentiation as Th2 and Tc2 cells transduced with T-bet produce IFN-{gamma} and repress IL-4 and IL-5 expression (17). T-bet plays a context-specific role in differentiation of CTL and activation of NK cells (18, 19, 20). Whereas in vitro-stimulated T-bet–/– CD8+ T cells produce normal levels of IFN-{gamma}, in vivo killing by Ag-specific T-bet–/– CTL is severely impaired (19). NK cells that develop in the absence of T-bet have an immature phenotype and are reduced in numbers due to increased apoptosis (20). However, these cells show only a marginal reduction in IFN-{gamma} production and cytotoxicity in response to in vitro cytokine stimulation, respond normally to poly(I:C) stimulation in vivo and promote control of murine CMV (MCMV) viral replication (20, 21). Thus, despite some developmental and differentiation defects, T-bet–/– NK and CTL can respond in vivo, possibly due to expression of other factors, such as the T-box transcription factor eomesodermin (Eomes) that counterbalances T-bet deficiency. Moreover, T-bet–/– mice in the transgenic adenocarcinoma mouse prostate background develop tumors with the same rate and kinetics as control animals (22). Nonetheless, the incidence of metastatic disease and the size of secondary nodules are increased in the absence of T-bet (22). Consequently, the immune response to cancer may reflect T-bet-independent control of tumor initiation and T-bet-dependent response to tumor spread. The mechanism underlying the susceptibility of T-bet-deficient mice to tumor metastasis is not understood.

To investigate the mechanism through which T-bet expression modulates later steps in cancer establishment and growth, we used the B16F10 melanoma model (23, 24). Both innate and adaptive immune cells contribute to the control of B16F10 metastasis, allowing analysis of both arms of the immune system (25, 26, 27, 28). In this study, we show that the in vivo NK response to tumor metastasis is highly dependent upon T-bet expression due to reduced cell survival and effector function. Although T-bet deficiency does not alter the protective effect of tumor vaccination, which depends on an adaptive immune response, T-bet-deficient nonimmune mice are extremely susceptible to metastatic spreading of B16F10 cells. We conclude that T-bet expression by NK cells is essential to protect against tumor metastasis and important for NK-mediated cross-talk between innate and adaptive immune systems in response to metastatic disease.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

T-bet–/– mice generated in our laboratory were backcrossed 13 generations to the C57BL/6 background. C57BL/6 mice were purchased from The Jackson Laboratory and Rag2–/– mice from Taconic Farms. T-bet–/– Rag2–/– double knockout (DKO) animals were generated by intercrossing T-bet–/– and Rag2–/– mice. hCD2-reverse tetracycline (Tet)-controlled transcriptional activator (rtTA) T-bet–/– and Tet operon-responsive element (TRE)-T-bet T-bet–/– transgenic mice were generated by integrating the Tet-inducible expression system (Invitrogen) in T-bet–/– mice as described in Ref. 29 . In brief, the rtTA linked to the hCD2 promoter (CD2) construct was injected into T-bet–/–-fertilized eggs to generate CD2-rtTA T-bet–/– mice. TRE placed upstream of the mouse T-bet cDNA construct was injected likewise to generate TRE-T-bet T-bet–/– mice. CD2-rtTA T-bet–/– and TRE-T-bet T-bet–/– transgenic mice were intercrossed to generate CD2-rtTA TRE-T-bet T-bet–/– (T-bet–/– CD2-Cond) animals. T-bet expression was induced in vivo by feeding T-bet–/– CD2-Cond with mouse chow containing 625 mg doxycyline (Dox)/Kg (Harlan Teklad) and water supplemented with 1 mg/ml Dox (Sigma-Aldrich) and 2% sucrose (Fisher Scientific). All mice were housed under specific pathogen-free conditions at the Harvard School of Public Health. Animal handling and experimental procedures were in accordance with institutional requirements for animal care and use.

Cells

B16F10 and B16-GM-CSF cells were a gift from G. Dranoff (Harvard Medical School, Boston, MA). YAC-1 cells were purchased from American Type Culture Collection.

Tumor vaccination

Performed as described in Ref. 26 . Briefly, B16-GM-CSF cells were collected and irradiated at 35 Gy, washed, and resuspended in PBS for s.c administration of 0.5 x 106 per mouse, in 100 µl.

Generation of activated NK cells

A-LAK cells were generated as described in Ref. 30 . In brief, splenocytes were harvested from age-matched wild-type (WT) and T-bet–/– mice. Cells were culture in complete RPMI 10 supplemented with 10% FBS (Sigma-Aldrich) and 1000 U/ml of human rIL-2 (hr-IL-2; kindly provided by Chiron Corporation, Emeryville, CA). After 3 days in culture, floating cells were carefully removed. Fresh RPMI 10 media supplemented with 1000 U/ml hrIL-2 was added and cells were cultured for an additional 4–5 days, when floating cells were removed and adherent cells harvested with a short incubation in 0.02% EDTA in PBS. T cells were depleted by positive selection with anti-CD4 (L3T4) and anti-CD8{alpha} (Ly-2) microbeads (Miltenyi Biotec). Remaining cells were 85–90% pure NK1.1+ DX5+ CD3– NK cells as analyzed by surface staining and FACS.

Competitive in vivo A-NK cell homing assay

Homing assays were performed as described (31). Briefly, WT and T-bet–/– A-NK cells generated as described above were labeled with 5-(and -6)-{[(4-chloromethyl)benzoyl]amino}tetramethylrhodamine (CMTMR) or CFSE (Invitrogen) and mixed at a 1:1 ratio. Ten to 15 x 106 mixed cells were injected i.v. into WT or T-bet–/– mice that had received 60,000 B16F10 melanoma cells i.v. 3 days prior. A total of 2 or 24 h after adoptive transfer of A-NK cells, 1 ml of blood, spleen, peripheral lymph nodes, mesenteric lymph nodes, liver, and lungs were harvested. Liver and lungs were treated for 30 min at 37°C with 0.5% collagenase type 2 (Worthington Biochemical). Single-cell suspensions stained with anti-NK1.1 mAb (BD Pharmingen) were analyzed by FACS. The homing index was calculated as the ratio between the number of NK1.1+CMTMR+ and NK1.1+CFSE+ cells retrieved divided by the ratio of NK1.1+CMTMR+ and NK1.1+CFSE+ cells in the input population.

In vitro cytotoxicity assay

Effectors. A-NK cells were generated as described above and used as effector cells in a standard 4-h 51Cr release assay. Targets: 1 x 106 B16F10 cells were labeled with 200 µCi of 51Cr (PerkinElmer) for 2 h at 37°C, extensively washed and plated at 10,000 cells per well. Effector cells were plated at the E:T ratio described in the figure. Spontaneous release was <20% of maximum release. Percent specific lysis was calculated as 100 x (cpm test sample – cpm spontaneous release)/(cpm total release – cpm spontaneous release).

Flow cytometry

Annexin V, 7-AAD, fluorochrome-conjugated mAb against NK1.1 (PK136), IFN-{gamma}, and others were purchased from BD Pharmingen and cells were stained as described (20). Intracellular staining for IFN-{gamma} was performed using Cytofix/Cytoperm (BD Biosciences) according to the manufacturer’s protocol 6 h after activation of A-NK cells with 10 ng/ml IL-12 and 10 ng/ml IL-18 (R&D Systems). After staining, data were collected on a FACSCalibur (BD Biosciences) and analyzed with CellQuest software (Tree Star).

Statistics

Data was analyzed using Microsoft Excel software and the two-tailed Student’s t test. The null hypothesis was rejected and differences were assumed to be significant at a value of p < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
T-bet deficiency increases susceptibility to B16F10 melanoma

T-bet–/– animals can control the development of primary tumors in a murine prostate cancer model as well as WT littermates. However, T-bet deficiency is associated with increased metastatic disease in the same model (22). The selective susceptibility to metastasis but not primary tumor formation suggested that specific cell types may be responsible for this split phenotype.

We chose the widely used B16F10 melanoma model of tumor metastasis to study homing and establishment of secondary tumor nodules, the later steps in the process of cancer spread. Both innate and adaptive immune cells constitute the anti-B16F10 response, and susceptibility of the host animals to melanoma is quantified by counting the number of pulmonary tumor nodules following i.v. injection of B16F10 cells. We first compared susceptibility of T-bet–/– and T-bet WT animals to B16F10 growth after i.v. injection at different days after inoculation. We observed a marked increase in the number of melanoma nodules in the lungs of T-bet–/– mice compared with WT littermate controls (Fig. 1, A and B). As early as 7 days after inoculation, over 1000 nodules could be seen on the surface of T-bet–/– lungs. Titration of the number of tumor cells transferred showed that 60,000 B16F10 cells injected i.v. were sufficient to generate over 160 nodules in the lungs of T-bet–/– mice 14 days after inoculation, at which point only ~2 nodules were detectable in WT counterparts (Fig. 1C). Histopathological analysis of the lungs of tumor-bearing WT and T-bet–/– animals confirmed the increase in frequency and also showed an increase in the size of melanoma nodules in this organ (data not shown). We conclude that T-bet–/– mice are highly susceptible to B16F10 melanoma, corroborating previous observations in the transgenic adenocarcinoma mouse prostate model of prostate cancer (22).


Figure 1
View larger version (48K):
[in this window]
[in a new window]

  		FIGURE 1. T-bet-deficient mice are highly susceptible to B16F10 melanoma challenge. WT and T-bet–/– animals were inoculated with 2 x 105 B16F10 melanoma cells i.v. Seven or 14 days later, mice were euthanized and the lungs dissected. Representative pictures of lungs (A) and the total number of melanoma nodules counted in these organs (B) are shown (n = 7). C, B16F10 cells were titrated and administered i.v. to WT and T-bet–/– mice. Number of tumor nodules in the lungs was analyzed 14 days after injection. Data are shown as average of total pulmonary nodules ± SD (n = 5).

 
T-bet deficiency in the innate immune system severely compromises antitumor response

The robust tumor growth observed as early as 7 days after melanoma inoculation into T-bet–/– mice suggested that the innate response to tumors might be compromised. FACS analysis of single-cell suspension of lungs 7 days after tumor injection showed no difference in the relative numbers of dendritic cells, macrophages, granulocytes, CD4+ cells, or CD8+ T cells between T-bet–/– and WT mice (data not shown). However, there was a 20-fold decrease in the proportions of NK cells and an absence of NKT cells in the lungs of T-bet–/– animals, a difference observed to a smaller extent in naive T-bet–/– animals (5-fold fewer NK cells in T-bet–/–) but which was accentuated by melanoma growth (Fig. 2A and data not shown). Both NK and NKT cells contribute to protective antitumor responses. NK cells display potent ex vivo cytolytic activity against tumor cells while NKT cells produce large amounts of IFN-{gamma} upon activation and show in vivo antitumor activity after stimulation with {alpha}-galactosyl ceramide (28, 32). We crossed T-bet–/– animals to mice that lack Rag2 expression to define the role of the NK response to B16F10 in the absence of T cells and NKT cells, which are virtually absent in Rag2–/– mice. Rag2–/– animals rejected B16F10 melanoma cells more efficiently than WT animals, possibly due to their increased NK numbers (data not shown) and lack of T regulatory cell-mediated suppression of NK cells (33). T-bet–/– and Rag2–/–T-bet–/– DKO mice displayed the same enhanced numbers of tumor nodules in the lungs, demonstrating that the lack of T and NKT cells does not alter the defective T-bet–/– phenotype (Fig. 2B).


Figure 2
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 2. T-bet-deficient innate immune system is largely responsible for susceptibility to melanoma. A, Fourteen days after inoculation with 60,000 B16F10 cells i.v. WT and T-bet–/– lungs were dissected. Representative FACS analysis of lung-infiltrating NK and NKT cells are shown (n = 5). B, Lungs of WT, T-bet–/–, Rag2–/–, and DKO animals analyzed 14 days after inoculation with 60,000 B16F10 cells i.v. Representative pictures of the lungs (left) and number of melanoma nodules on the surface of this organ (right) are shown. Data are shown as average of total pulmonary nodules ± SD (n = 5). C, T-bet–/– CD2-Cond mice were treated with Dox in food and water from 4 days before inoculation of 2 x 106 B16F10 cells i.v. to the end of the experiment. Twenty one days after inoculation, mice were euthanized and the lungs dissected. Total number of pulmonary tumor nodules is shown as mean ± SD (n = 4–10). Data are representative of three independent experiments. D, WT and T-bet–/– mice were vaccinated with 0.5 x 106 irradiated B16-GM-CSF and challenged with 0.2 x 106 live B16F10 cells i.v. 14 days later. Analysis of the total number of tumor nodules in the lungs was done 14 days after B16F10 challenge. Data are shown as mean ± SD (n = 3–4) and are representative of two independent experiments.

 
These results may reflect either the absence of a T cell contribution to tumor protection or failure to prime T cells in T-bet –/– mice. To address this question, we selectively expressed T-bet in T cells of T-bet–/– animals and assessed susceptibility to B16F10 challenge. To this end, we generated T-bet–/– Tet on transgenic mice where rtTA is constitutively expressed under the hCD2 promoter (T-bet–/– CD2-Cond). Upon Dox administration, rtTA binds to TRE and drives expression of Flag-tagged T-bet. In vivo treatment with Dox led to physiological levels of T-bet expression by T-bet–/– CD2-Cond T cells and restored the Th1 phenotype of T-bet–/– CD4+ T cells, which otherwise display a tendency toward Th2 differentiation upon stimulation (21). Activation of T-bet–/– CD2-Cond CD4+ T cells leads to expression of IL-2 and lack of IFN-{gamma}. In the presence of Dox, expression of IL-2 is unimpaired while IFN-{gamma} is up-regulated (data not shown). Expression of T-bet by NK cells in this system is small, reaching <40% of WT levels (data not shown). We then tested the susceptibility of T-bet–/– CD2-Cond mice to B16F10 tumor growth. WT, T-bet–/–, and T-bet–/– CD2-Cond mice received B16F10 cells 3–5 days after starting in vivo Dox treatment in food and water, and Dox administration was maintained throughout the experiment. Despite robust induction of T-bet expression (data not shown), the growth of pulmonary B16F10 nodules was not altered by Dox administration to T-bet–/– CD2-Cond animals compared with T-bet–/– mice that underwent the same regimen; both groups developed ~350 nodules 21 days after tumor challenge, compared with ~40 of WT controls (Fig. 2C). Therefore, expression of T-bet in the T cell compartment does not protect T-bet–/– animals from B16F10 melanoma growth.

The induction of T cell responses is a complex process that requires immune recognition and Ag presentation by cells of the innate immune system. Although the absence of T cells does not increase susceptibility to tumor growth and expression of T-bet in T cells fails to protect T-bet–/– mice, it is possible that T lymphocytes in T-bet–/– hosts are not properly activated rather than intrinsically defective. We used the B16-GM-CSF vaccination protocol, which stimulates a potent CTL response against subsequent B16F10 challenge in a dendritic cell (DC) and CD4+ T cell-dependent manner (26), to determine whether the lack of T cell response in tumor-bearing T-bet–/– animals was due to inefficient stimulation of T cells by members of the innate immune system. In agreement with previous reports, vaccination of WT mice with irradiated B16-GM-CSF cells before challenge with live B16F10 cells protected the animals to the extent that no tumor nodules were detected in the lungs of vaccinated mice. T-bet–/– mice were highly protected from B16F10 challenge upon vaccination, displaying a 10-fold reduction in tumor nodules when compared with mock-vaccinated animals (Fig. 2D). This result demonstrates that T-bet–/– lymphocytes are able to mount an effective anti-melanoma response if properly stimulated, and suggest that GM-CSF-induced DC activation overcomes T-bet deficiency.

Transfer of WT A-NK cells restores tumor immunity to T-bet–/– animals

We tested the capacity of NK cells to protect T-bet–/– animals by transferring WT NK cells to these mice after tumor challenge and assessing tumor growth in the lungs. We generated activated NK cells in vitro by collecting the adherent portion of lymphokine-activated killer (A-LAK) cell cultures. A-LAK cells transferred into tumor-bearing hosts infiltrate pulmonary melanoma nodules and promote tumor immunity both in mice and humans (34, 35, 36). A-LAK cells from WT and T-bet–/– splenocytes were enriched for NK cells (A-NK) and adoptively transferred into T-bet–/– animals shortly after tumor challenge. Similar numbers of A-NK cells were recovered from both T-bet–/– and WT cultures, as expected from previous studies of T-bet–/– NK cells (data not shown and Ref. 20). Transfer of WT A-NK cells early after melanoma challenge protected T-bet–/– mice, as judged by a significant delay in pulmonary tumor growth and reduction in size and numbers of melanoma nodules compared with T-bet–/– mice that received PBS only (Fig. 3). Moreover, transfer of T-bet–/– A-NK cells did not protect T-bet–/– recipients (Fig. 3). These observations indicate that reconstitution of the NK compartment of T-bet–/– mice with WT NK cells delays B16F10 tumor growth, suggesting that T-bet–/– NK cells have intrinsic defects that render them unable to control pulmonary tumor metastasis.


Figure 3
View larger version (49K):
[in this window]
[in a new window]

  		FIGURE 3. Transfer of WT NK cells protects T-bet–/– animals from tumor challenge. Approximately 10 x 106 WT or T-bet–/– A-NK cells were transferred into tumor-bearing T-bet–/– mice i.v. 1 and 3 days after tumor inoculation. Control tumor-bearing WT and T-bet–/– mice received PBS. Fourteen days after B16F10 injection mice were euthanized and the lungs dissected. Representative pictures of the lungs (A) and quantification of melanoma nodules on the surface of these organs (B) are shown. Data are shown as mean ± SD (n = 9) and is representative of three independent experiments.

 
T-bet deficiency does not impair A-NK cell recruitment to the lungs but reduces A-NK in vivo survival

The failure of T-bet–/– A-NK cells to protect mice after B16F10 challenge may be due to the inability of these cells to migrate into relevant organs or, following successful organ infiltration, to impaired effector function. Because T-bet–/– animals can develop chronic lung inflammation (37), we asked whether migration of A-NK cells was altered in T-bet–/– hosts compared with their WT counterparts. After labeling WT and T-bet–/– A-NK cells with different fluorescent dyes, a 1:1 mixture of these cells was adoptively transferred into WT or T-bet–/– mice and FACS analysis was performed. No difference in the recovery ratio of WT and T-bet–/– A-NK cells was observed 2 h after injection, demonstrating that 1) homing of T-bet–/– and WT A-NK cells is not distinguishable; and 2) WT and T-bet–/– hosts support A-NK cell homing equally well (Fig. 4A). Analyses by confocal microscopy of WT tumor-bearing lungs 2 h after A-NK cell transfer were consistent with these conclusions (data not shown), and similar number/distribution of transferred NK cells were noted independently of the reagent used to label WT and T-bet–/– A-NK cells (data not shown).


Figure 4
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 4. T-bet–/– A-NK cells show normal recruitment but reduced survival in vivo. WT and T-bet–/– A-NK cells were labeled with CFSE or CMTMR, respectively, mixed at a 1:1 ratio, and injected i.v. into tumor-bearing WT or T-bet–/– mice. Two hours after NK cell transfer, mice were euthanized and the lungs dissected and prepared for FACS analysis (A). A, Single-cell suspension of the lungs was gated on NK1.1+ cells and the ratio between CFSE- and CMTMR-labeled cells established. Data are shown as the ratio between WT:T-bet–/– cells recovered (n = 3) and is representative of four independent experiments. B, Experiment was performed as in A. Data are shown as the ratio between WT:T-bet–/– cells recovered from lungs of WT hosts 2 and 24 h after transfer (n = 3), and is representative of four independent experiments. Similar results were obtained when the dyes used to stain WT and T-bet–/– A-LAK cells were inverted (data not shown).

 
These observations suggest that T-bet–/– A-NK cells have normal migration patterns and that tumor-bearing T-bet–/– hosts are as efficient as tumor-bearing WT mice in promoting A-NK recruitment to lymphoid and nonlymphoid organs. We then asked whether T-bet–/– A-NK cells were as robust as their WT counterparts and present in the lungs and spleen of host mice at later time points after adoptive transfer. After labeling as described, we compared the recovery of T-bet–/– and WT A-NK cell mixtures 2 and 24 h after i.v. transfer into WT tumor-bearing hosts. Although equal numbers of lung- and spleen-infiltrating WT and T-bet–/– A-NK cells can be recovered 2 h after transfer (Fig. 4B), at 24 h, WT A-NK cells were 10 times more abundant than their T-bet–/– counterparts in both lungs and spleen (Fig. 4B). These results suggest that T-bet–/– A-NK cells have reduced in vivo longevity when compared with WT A-NK cells (Fig. 3).

Lack of T-bet expression reduces A-NK cell survival and effector function

Because T-bet–/– A-NK cells show reduced in vivo survival upon transfer into tumor-bearing hosts, augmented NK cell death following activation may contribute to the susceptibility of T-bet–/– mice to tumor metastasis. In addition, T-bet–/– A-NK cells may harbor other intrinsic defects that hinder antitumor effector function. Analysis of these cells 5 days after stimulation with IL-2 revealed decreased lysis of B16F10 cells in a 4-h 51Cr-release assay when compared with WT A-NKs (Fig. 5A). Similar results were obtained when YAC-1 cells were used as targets (data not shown). Expression of IFN-{gamma} by T-bet–/– A-NK cells after IL-12/IL-18 stimulation was also markedly decreased when compared with their WT counterparts (Fig. 5B). Furthermore, T-bet–/– A-NK cells displayed increased apoptosis after culture, corroborating with our in vivo data (Fig. 5C). Taken together, these results suggest that the reduced life-span of T-bet–/– A-NK cells observed after in vivo transfer is associated with an apoptotic phenotype and impaired effector function.


Figure 5
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 5. T-bet–/– A-NK cells have decreased effector function and are prone to apoptosis. A, Cytotoxicity of WT and T-bet–/– A-NK cells was tested against 51Cr-labeled B16F10 cells in a 4-h 51Cr release assay (n = 2). WT and T-bet–/– A-NK cells were stimulated for 6 h with IL-12/IL-18 and stained for intracellular IFN-{gamma} and NK1.1 (B), or left un-stimulated and stained with AnnexinV and NK1.1 (C). FACS analysis followed. Representative plots of two independent experiments are shown.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Effective in vivo immune responses against growing tumors rely on a strong activation of NK, NKDC, and CTLs (9, 10, 26, 36). In intact hosts, this level of stimulation is rarely achieved due to active suppression of the initial response and/or weak agonistic stimulation by tumor Ags (33). However, several groups have demonstrated that the host immune system can successfully retard tumor progression through enhanced cytotoxic activity and IFN-{gamma} production associated with type 1 immunity (1, 2, 3, 4, 5, 6).

The transcription factor T-bet is a key transcriptional regulator of type 1 immunity that promotes differentiation of Th1 and Tc1 cells, B cell class switch, and the expression of type 1 cytokines and cytokine receptors (17, 19, 21, 38, 39, 40). Whereas DCs and NKT cells depend on T-bet expression to sustain type 1 responses (20, 38, 41), the role of T-bet in NK and CTLs can be shared or supplemented by Eomes, another member of the T-box family of transcription factors (18, 42). As a result, stimuli that induce Eomes in NK and CTL may compensate for maturation issues due to T-bet deficiency and contribute to resistance to MCMV infection and response to poly(I:C) stimulation in T-bet-deficient mice (20, 21). In the case of antitumor responses, T-bet is essential for the control of tumor metastasis, but the mechanism of T-bet-dependent resistance is not understood (22).

In this study, we have used B16F10 i.v. challenge, an established murine model of cancer metastatic disease, to isolate events relevant to tumor metastasis. The already reduced number of lung-infiltrating NK and NKT cells in T-bet–/– mice fails to increase after tumor challenge, leading to a 20-fold reduction of NK cells and no NKT cells infiltrating tumor-bearing tissue (20). In the context of tumors, NK and DCs form an axis that can promote cancer cell death, subsequent presentation of tumor Ags to T cells and may lead to helper-independent activation of CTLs (43). Our data demonstrate that although in vivo expression of T-bet in T cells does not protect T-bet–/– mice, prophylactic vaccination with tumor cells engineered to express GM-CSF leads to a significant decrease in metastatic disease. These results are consistent with previous reports that T-bet–/– CTLs and NK cells can respond efficiently to stimuli that induce Eomes activation and suggest that T-bet–/– DCs are successful in inducing an adaptive response when stimulated with GM-CSF (44). However, these data also demonstrate that in T-bet–/– naive hosts, the response initiated by B16F10 tumor growth does not induce such potent activation. We rule out tumor-induced natural regulatory T cell-mediated suppression of antitumor responses as well as the role of NKT cells by showing that T-bet–/– Rag2–/– doubly deficient mice (DKO) are as susceptible as T-bet–/–Rag2+/+ animals to B16F10 melanoma (33, 45, 46, 47, 48). These results also show that the lack of T and NKT cells does not increase susceptibility of T-bet–/– to B16F10, suggesting that T-bet deficiency in innate immune cells disables both innate and adaptive immune responses.

NK cells are an important component of the innate immune system and especially implicated in antitumor immunity. These cells can hinder tumor progression directly by perforin/granzyme-mediated cytolytic activity and production of the inflammatory cytokine IFN-{gamma}, which independently inhibit tumor survival and growth or indirectly by activating and providing tumor Ags to professional APCs, which then induce an adaptive response to the tumor (4, 12, 13, 14, 49, 50, 51, 52, 53). Their ability to sense small changes in cellular homeostasis and quickly respond confers a great potential to recognize and eliminate transformed cells (50). We show that these characteristics depend on T-bet expression because transfer of T-bet+/+ but not T-bet–/– activated NK cells before or after B16F10 inoculation conferred protection to T-bet–/– hosts. The altered maturation of T-bet–/– NK cells is not responsible for the global impairment of effector function because T-bet–/– mice efficiently control MCMV virus titers and T-bet–/– NK cells respond to poly(I:C) stimulation (20, 21). Further analysis showed that decreased IFN-{gamma} production and modest lytic activity of T-bet–/– NK cells upon IL-2 stimulation may be accentuated by their reduced viability in vitro and in vivo. These results demonstrate that T-bet-dependent NK cell longevity and function is essential for inhibition of metastatic development. In the absence of T-bet, NK cells do not mediate the crosstalk between innate and adaptive immunity, rendering the host highly susceptible to tumor spread. These observations open the possibility that T-bet polymorphisms may correlate with increased clinical metastatic disease as well as they do with asthma incidence (54), and suggests that therapies which augment T-bet expression in NK cells may ameliorate control of tumor spread.


   Acknowledgments
 
We thank Dr. Diefenbach for assistance with confocal microscopy, Dorothy Hu for assistance with histotology, Dr. Kim and Dr. Nolting for critical reading of this manuscript, Alison Angel for assistance with manuscript and figure editing, and Landy Kangalo, Jacobo Ramirez, Antonia Garcia, and Dina Laznik for technical assistance. M.B.F.W. thanks F.F.W., S.A.B., and I.B.F.W. for unconditional support.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
L.H.G. holds equity in and is on the Corporate Board of Directors of the Bristol-Myers Squibb Pharmaceutical Company.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by National Institutes of Health Grants AI12184 (to H.C.), AI46125 (to H.C.), CA112663 (to L.H.G.), AI31541 (to L.H.G. and G.L.-V.), and Seoul Research and Business Development Program, NCC 0620380 (to E.S.H.). Back

2 Current address: Section of Cell and Developmental Biology, University of California, San Diego, 9500 Gilman Drive, Natural Sciences Building 6104, La Jolla, CA 92093. Back

3 Address correspondence and reprint requests to Dr. Harvey I. Cantor, Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. E-mail address: Harvey_Cantor{at}dfci.harvard.edu or Dr. Laurie H. Glimcher, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, François-Xavier Baqnoud building, Boston, MA 02115. E-mail address: lglimche{at}hsph.harvard.edu Back

4 Abbreviations used in this paper: Tc, T cytotoxic; DKO, double knockout; Dox, doxicycline; Tet, tetracycline; rtTA, reverse Tet-controlled transcriptional activator; TRE, Tet-responsive element; MCMV, murine CMV; h, human; WT, wild type; DC, dendritic cell; Eomes, eomesodermin; CMTMR, 5-(and-6)-{[(4-chloromethyl)benzoyl]amino}tetramethylrhodamine. Back

Received for publication December 4, 2007. Accepted for publication April 9, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, R. D. Schreiber. 2001. IFN{gamma} and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111. [Medline]
  2. Smyth, M. J., K. Y. Thia, S. E. Street, D. MacGregor, D. I. Godfrey, J. A. Trapani. 2000. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192: 755-760. [Abstract/Free Full Text]
  3. Willimsky, G., T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141-146. [Medline]
  4. van den Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184: 1781-1790. [Abstract/Free Full Text]
  5. Dunn, G. P., A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri, J. D. Bui, M. S. Diamond, C. M. Koebel, C. Arthur, J. M. White, R. D. Schreiber. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6: 722-729. [Medline]
  6. Swann, J. B., M. J. Smyth. 2007. Immune surveillance of tumors. J. Clin. Invest. 117: 1137-1146. [Medline]
  7. Zamai, L., C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, M. Vitale. 2007. NK cells and cancer. J. Immunol. 178: 4011-4016. [Abstract/Free Full Text]
  8. Ikeda, H., K. Chamoto, T. Tsuji, Y. Suzuki, D. Wakita, T. Takeshima, T. Nishimura. 2004. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 95: 697-703. [Medline]
  9. Chan, C. W., E. Crafton, H. N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. Brockstedt, T. W. Dubensky, M. F. Stins, L. L. Lanier, et al 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12: 207-213. [Medline]
  10. Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. Pequignot, N. Casares, M. Terme, C. Flament, et al 2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12: 214-219. [Medline]
  11. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90. [Medline]
  12. Kakuta, S., Y. Tagawa, S. Shibata, M. Nanno, Y. Iwakura. 2002. Inhibition of B16 melanoma experimental metastasis by interferon-{gamma} through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105: 92-100. [Medline]
  13. Rodrigues, E. G., A. S. Garofalo, L. R. Travassos. 2002. Endogenous accumulation of IFN-{gamma} in IFN-{gamma}-R(–/–) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-{gamma} anti-tumor cytotoxicity in vitro and in vivo. Cytokines Cell. Mol. Ther. 7: 107-116. [Medline]
  14. Moretta, L., G. Ferlazzo, C. Bottino, M. Vitale, D. Pende, M. C. Mingari, A. Moretta. 2006. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214: 219-228. [Medline]
  15. Dobrzanski, M. J., J. B. Reome, R. W. Dutton. 2001. Immunopotentiating role of IFN-{gamma} in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98: 70-84. [Medline]
  16. Marcenaro, E., C. M. Della, F. Bellora, S. Parolini, R. Millo, L. Moretta, A. Moretta. 2005. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J. Immunol. 174: 3992-3998. [Abstract/Free Full Text]
  17. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669. [Medline]
  18. Glimcher, L. H., M. J. Townsend, B. M. Sullivan, G. M. Lord. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4: 900-911. [Medline]
  19. Sullivan, B. M., A. Juedes, S. J. Szabo, M. von Herrath, L. H. Glimcher. 2003. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl. Acad. Sci. USA 100: 15818-15823. [Abstract/Free Full Text]
  20. Townsend, M. J., A. S. Weinmann, J. L. Matsuda, R. Salomon, P. J. Farnham, C. A. Biron, L. Gapin, L. H. Glimcher. 2004. T-bet regulates the terminal maturation and homeostasis of NK and V{alpha}14i NKT cells. Immunity 20: 477-494. [Medline]
  21. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, L. H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-{gamma} production in CD4 and CD8 T cells. Science 295: 338-342. [Abstract/Free Full Text]
  22. Peng, S. L., M. J. Townsend, J. L. Hecht, I. A. White, L. H. Glimcher. 2004. T-bet regulates metastasis rate in a murine model of primary prostate cancer. Cancer Res. 64: 452-455. [Abstract/Free Full Text]
  23. Fidler, I. J.. 1975. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35: 218-224. [Abstract/Free Full Text]
  24. Khanna, C., K. Hunter. 2005. Modeling metastasis in vivo. Carcinogenesis 26: 513-523. [Abstract/Free Full Text]
  25. Dobrzanski, M. J., J. B. Reome, R. W. Dutton. 1999. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J. Immunol. 162: 6671-6680. [Abstract/Free Full Text]
  26. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543. [Abstract/Free Full Text]
  27. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668. [Abstract/Free Full Text]
  28. Smyth, M. J., N. Y. Crowe, D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463. [Abstract/Free Full Text]
  29. Legname, G., B. Seddon, M. Lovatt, P. Tomlinson, N. Sarner, M. Tolaini, K. Williams, T. Norton, D. Kioussis, R. Zamoyska. 2000. Inducible expression of a p56Lck transgene reveals a central role for Lck in the differentiation of CD4 SP thymocytes. Immunity 12: 537-546. [Medline]
  30. Gunji, Y., N. L. Vujanovic, J. C. Hiserodt, R. B. Herberman, E. Gorelik. 1989. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J. Immunol. 142: 1748-1754. [Abstract]
  31. Weninger, W., M. A. Crowley, N. Manjunath, U. H. von Andrian. 2001. Migratory properties of naive, effector, and memory CD8+ T cells. J. Exp. Med. 194: 953-966. [Abstract/Free Full Text]
  32. Smyth, M. J., N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita, D. I. Godfrey. 2002. Sequential production of interferon-{gamma} by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of {alpha}-galactosylceramide. Blood 99: 1259-1266. [Abstract/Free Full Text]
  33. Ghiringhelli, F., C. Menard, F. Martin, L. Zitvogel. 2006. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214: 229-238. [Medline]
  34. Albertsson, P. A., P. H. Basse, M. Hokland, R. H. Goldfarb, J. F. Nagelkerke, U. Nannmark, P. J. Kuppen. 2003. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24: 603-609. [Medline]
  35. Basse, P., R. B. Herberman, U. Nannmark, B. R. Johansson, M. Hokland, K. Wasserman, R. H. Goldfarb. 1991. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 174: 479-488. [Abstract/Free Full Text]
  36. Ljunggren, H. G., K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339. [Medline]
  37. Finotto, S., M. F. Neurath, J. N. Glickman, S. Qin, H. A. Lehr, F. H. Green, K. Ackerman, K. Haley, P. R. Galle, S. J. Szabo, et al 2002. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295: 336-338. [Abstract/Free Full Text]
  38. Lugo-Villarino, G., R. Maldonado-Lopez, R. Possemato, C. Penaranda, L. H. Glimcher. 2003. T-bet is required for optimal production of IFN-{gamma} and antigen-specific T cell activation by dendritic cells. Proc. Natl. Acad. Sci. USA 100: 7749-7754. [Abstract/Free Full Text]
  39. Peng, S. L., S. J. Szabo, L. H. Glimcher. 2002. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. USA 99: 5545-5550. [Abstract/Free Full Text]
  40. Shinohara, M. L., M. Jansson, E. S. Hwang, M. B. Werneck, L. H. Glimcher, H. Cantor. 2005. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 102: 17101-17106. [Abstract/Free Full Text]
  41. Lugo-Villarino, G., S. Ito, D. M. Klinman, L. H. Glimcher. 2005. The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc. Natl. Acad. Sci. USA 102: 13248-13253. [Abstract/Free Full Text]
  42. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043. [Abstract/Free Full Text]
  43. Adam, C., S. King, T. Allgeier, H. Braumuller, C. Luking, J. Mysliwietz, A. Kriegeskorte, D. H. Busch, M. Rocken, R. Mocikat. 2005. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106: 338-344. [Abstract/Free Full Text]
  44. Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. Mullen, C. R. Gasink, S. M. Kaech, J. D. Miller, et al 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244. [Medline]
  45. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor {alpha}) monoclonal antibody. Cancer Res. 59: 3128-3133. [Abstract/Free Full Text]
  46. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, C. J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832. [Abstract/Free Full Text]
  47. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, C. H. June. 2002. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168: 4272-4276. [Abstract/Free Full Text]
  48. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, C. H. June. 2001. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772. [Abstract/Free Full Text]
  49. Degli-Esposti, M. A., M. J. Smyth. 2005. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5: 112-124. [Medline]
  50. Di Santo, J. P.. 2006. Natural killer cell developmental pathways: a question of balance. Annu. Rev. Immunol. 24: 257-286. [Medline]
  51. Kodama, T., K. Takeda, O. Shimozato, Y. Hayakawa, M. Atsuta, K. Kobayashi, M. Ito, H. Yagita, K. Okumura. 1999. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29: 1390-1396. [Medline]
  52. Smyth, M. J., K. Y. Thia, E. Cretney, J. M. Kelly, M. B. Snook, C. A. Forbes, A. A. Scalzo. 1999. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162: 6658-6662. [Abstract/Free Full Text]
  53. Street, S. E., E. Cretney, M. J. Smyth. 2001. Perforin and interferon-{gamma} activities independently control tumor initiation, growth, and metastasis. Blood 97: 192-197. [Abstract/Free Full Text]
  54. Raby, B. A., E. S. Hwang, K. Van Steen, K. Tantisira, S. Peng, A. Litonjua, R. Lazarus, C. Giallourakis, J. D. Rioux, D. Sparrow, et al 2006. T-bet polymorphisms are associated with asthma and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 173: 64-70. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. H. Esensten, M. R. Lee, L. H. Glimcher, and J. A. Bluestone
T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function
J. Immunol., July 1, 2009; 183(1): 75 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Elkabets, Y. Krelin, S. Dotan, A. Cerwenka, A. Porgador, R. G. Lichtenstein, M. R. White, M. Zoller, Y. Iwakura, C. A. Dinarello, et al.
Host-Derived Interleukin-1{alpha} Is Important in Determining the Immunogenicity of 3-Methylcholantrene Tumor Cells
J. Immunol., April 15, 2009; 182(8): 4874 - 4881.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Sauer, J. H. Maxeiner, R. Karwot, P. Scholtes, H. A. Lehr, M. Birkenbach, R. S. Blumberg, and S. Finotto
Immunosurveillance of Lung Melanoma Metastasis in EBI-3-Deficient Mice Mediated by CD8+ T Cells
J. Immunol., November 1, 2008; 181(9): 6148 - 6157.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werneck, M. B. F.
Right arrow Articles by Glimcher, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werneck, M. B. F.
Right arrow Articles by Glimcher, L. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS